Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Archive ouverte

Fontan, Charlotte | Tiab, Mourad | Godmer, Pascal | Luycx, Odile | Allangba, Olivier | Pignon, Jean-Michel | Fuzibet, Jean-Gabriel | Legros, Laurence | Stoppa, Anne Marie | Dib, Mamoun | Pegourie, Brigitte | Orsini-Piocelle, Frederique | Karlin, Lionel | Arnulf, Bertrand | Roussel, Murielle | Garderet, Laurent | Mohty, Mohamad | Meuleman, Nathalie | Doyen, Chantal | Lenain, Pascal | Macro, Margaret | Leleu, Xavier | Facon, Thierry | Moreau, Philippe | Attal, Michel | Avet-Loiseau, Hervé | Dejoie, Thomas | Corre, Jill | Caillon, Hélène | Hulin, Cyrille | Perrot, Aurore | Caillot, Denis | Boyle, Eileen | Chrétien, Marie-Lorraine | Fontan, Jean | Belhadj, Karim | Bréchignac, Sabine | Decaux, Olivier | Voillat, Laurent | Rodon, Philippe | Fitoussi, Olivier | Araujo, Carla | Benboubker, Lotfi

Edité par CCSD ; American Society of Hematology -

International audience. Guidelines for monitoring multiple myeloma (MM) patients expressing light chains only (light-chain MM [LCMM]) rely on measurements of monoclonal protein in urine. Alternatively, serum free light chain (sFLC) measurements have better sensitivity over urine methods, however, demonstration that improved sensitivity provides any clinical benefit is lacking. Here, we compared performance of serum and urine measurements in 113 (72κ, 41λ) newly diagnosed LCMM patients enrolled in the Intergroupe Francophone du Myélome (IFM) 2009 trial. All diagnostic samples (100%) had an abnormal κ:λ sFLC ratio, and involved (monoclonal) FLC (iFLC) expressed at levels deemed measurable for monitoring (≥100 mg/L). By contrast, only 64% patients had measurable levels of monoclonal protein (≥200 mg per 24 hours) in urine protein electrophoresis (UPEP). After 1 and 3 treatment cycles, iFLC remained elevated in 71% and 46% of patients, respectively, whereas UPEP reported a positive result in 37% and 18%; all of the patients with positive UPEP at cycle 3 also had elevated iFLC levels. Importantly, elevated iFLC or an abnormal κ:λ sFLC ratio after 3 treatment cycles associated with poorer progression-free survival (P = .006 and P < .0001, respectively), whereas positive UPEP or urine immunofixation electrophoresis (uIFE) did not. In addition, patients with an abnormal κ:λ sFLC ratio had poorer overall survival (P = .022). Finally, early normalization of κ:λ sFLC ratio but not negative uIFE predicted achieving negative minimal residual disease, as determined by flow cytometry, after consolidation therapy (100% positive predictive value). We conclude that improved sensitivity and prognostic value of serum over urine measurements provide a strong basis for recommending the former for monitoring LCMM patients.

Consulter en ligne

Suggestions

Du même auteur

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Archive ouverte | Moreau, Philippe | CCSD

International audience. Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with newly diagnosed mul...

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Archive ouverte | Perrot, Aurore | CCSD

IF 15.132 (2017). International audience. The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, healt...

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Archive ouverte | Leleu, Xavier | CCSD

International audience. The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM). However, we observed a ...

Chargement des enrichissements...